Form 4: RenovoRx Chief Medical Officer Granted 63,636 Stock Options

RenovoRx, Inc. has granted 63,636 non-qualified stock options to its Chief Medical Officer and Director, Ramtin Agah, under the company's Amended and Restated 2021 Omnibus Equity Incentive Plan.

Summary

• Ramtin Agah, Chief Medical Officer and Director of RenovoRx, Inc. (RNXT), was granted 63,636 non-qualified stock options.
• The options were awarded under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan.
• The grant was approved by the Compensation Committee of the Board of Directors on July 1, 2025.
• The exercise price for these options is $1.27 per share.
• The options vest at a rate of 1/48 per month over four years, with vesting commencing on January 1, 2025.
• Full vesting is expected by January 1, 2029.
• The options will expire on July 1, 2035.
• Exercisability is contingent upon an effective registration statement covering the underlying shares.
• The award was previously allocated for services rendered, with issuance contingent on share availability under the Plan, which became effective after stockholder approval on June 24, 2025.

Sentiment

Score: 6

Explanation: The document reports a routine executive compensation event (stock option grant) which is generally positive as it aligns management incentives with shareholder interests. There are no negative financial or operational disclosures.

Positives

• Granting of stock options to a key executive aligns management's interests with those of shareholders, incentivizing long-term performance.
• The award was approved by the Compensation Committee and contingent on stockholder approval of the plan, indicating proper corporate governance.

Risks

• The options will only become exercisable when there is an effective registration statement covering the shares underlying the option, introducing a contingency.

Future Outlook

The 63,636 non-qualified stock options granted to Ramtin Agah will vest monthly over four years, commencing January 1, 2025, and will be fully vested by January 1, 2029. The options are exercisable until July 1, 2035, provided an effective registration statement covering the underlying shares is in place.

Management Comments

• The award of 63,636 non-qualified options was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025.
• The award represents options previously allocated for services rendered, contingent on share availability under the Plan, which became effective upon stockholder approval on June 24, 2025.

Industry Context

Executive compensation, particularly through equity grants like stock options, is a standard practice across the biotechnology and pharmaceutical industries. These grants are designed to attract, retain, and incentivize key talent by aligning their financial interests with the long-term performance of the company and its shareholders. The structure of vesting over several years is typical for such incentive plans.

Comparison to Industry Standards

• The vesting schedule of 1/48 per month over four years with no cliff is a common industry practice for executive equity grants, promoting long-term retention.
• The requirement for an effective registration statement for exercisability is a standard regulatory compliance measure for publicly traded shares.
• Without specific details on RenovoRx's stage of development, market capitalization, or typical compensation packages for Chief Medical Officers at comparable biotech firms, a direct quantitative comparison of the option grant size (63,636 options) is not feasible from this document alone. However, the mechanism of the grant aligns with general industry norms for incentivizing key personnel.

Corporate Governance

Related Party Transactions

• The grant of stock options to Ramtin Agah, a Director and Chief Medical Officer, constitutes a transaction with a related party (an insider) as a form of executive compensation.

Stakeholder Impact

• Shareholders: The grant of options could lead to potential future dilution if exercised, but it also serves to align the interests of a key executive with long-term shareholder value creation.
• Employees: This specific filing pertains to a single executive, but it reflects the company's overall compensation strategy, which can impact employee morale and retention.

Next Steps

• The options will continue to vest monthly at a rate of 1/48 per month until fully vested on January 1, 2029.
• An effective registration statement covering the underlying shares will be required for the options to become exercisable.

Key Dates

Keywords

RenovoRx, RNXT, Ramtin Agah, stock options, executive compensation, insider transaction, Form 4, equity incentive plan, beneficial ownership, Chief Medical Officer, Director